Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.

• Main Authors: Brandon A Berger (Author), Alexandra Cossio (Author), Nancy Gore Saravia (Author), Maria Del Mar Castro (Author), Sergio Prada (Author), Allison H Bartlett (Author), Mai T Pho (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2017-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BACKGROUND:Oral miltefosine has been shown to be non-inferior to first-line, injectable meglumine antimoniate (MA) for the treatment of cutaneous leishmaniasis (CL) in children. Miltefosine may be administered via in-home caregiver Directly Observed Therapy (cDOT), while patients must travel to clin...